Notice of Intent: Analytics Drug Research Advisor, OFF-X (Translational Safety/Toxicology), and Cortellis Drug Discovery Intelligence Software   2

INTRODUCTION

PURSUANT TO FAR Subpart 5.2 Synopses of Proposed Contract Actions, THIS IS A PRE-SOLICITATION NOTICE OF A PROPOSED CONTRACT TO ACTION.

THIS IS A PRE-SOLICITATION NON-COMPETITIVE NOTICE OF INTENT TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).

The National Institute on Drug Abuse (NIDA), Contracts Management Branch Red (CMB) on behalf of the NIDA, Intramural Research Program (NIDA-IRP) intends to award a sole source contract to Clarivate Analytics for a software subscription and user license to the Drug Research Advisor, OFF-X (Translational Safety/Toxicology), and Cortellis Drug Discovery Intelligence software application with BioMarkers Module from Clarivate Analytics LLC without providing for full or open competition.

REGULATORY AUTHORITY

The resultant contract will include all applicable provisions and clauses of the Federal Acquisition Regulation (FAR) in effect through the Federal Acquisition Circular (FAC) 2021-04.

STATUTORY AUTHORITY

This acquisition is conducted as non-competitive under the authority of 41 U.S.C. 253(c) under provisions of the statutory authority of FAR Subpart 6.302-1 Only one responsible source and no other supplies or services will satisfy agency requirements.

DESCRIPTION OF REQUIREMENT

The Office of Translational Initiatives and Program Innovations (OTIPI) is seeking to renew its user license and subscription to the Clarivate Analytics Drug Research Advisor, OFF-X (Translational Safety/Toxicology), and Cortellis Drug Discovery Intelligence software application. OTIPI has used the Drug Research Advisor and Cortellis Drug Discovery Intelligence software application software since 2014 and completed various projects related to the SBIR/STTR Business Program and Translational Initiatives. The database is used a) to identify Pharmaceutical companies interested in investing in NIDA funded SBIR/STTR companies; b) to identify promising drugs, formulations, and models which are not currently used in the substance abuse ecosystem, and c) to identify the history of the research and development related to the specific biological target. The OFF-X (Translational Safety/Toxicology) is an integrated application platform which will enable OTIPI to expand its capabilites.

Purpose and Objectives

The Integrity Internet Access subscription from Clarivate Analytics supported OTIPI's SBIR/STTR Business Program, Ladder U18 program (Value Ladder: climbing out of valley of death), and various Translational Initiatives. The SBIR/STTR Business Program utilizes the database to identify Pharmaceutical companies interested in investing in NIDA funded SBIR/STTR companies. The Translational and U18 Initiatives uses this software to identify promising drugs, formulations, and models in the development phase that are not currently used in the substance abuse ecosystem.

Period of Performance:

The estimated period of performance shall be 04/1/2021 through 03/31/2022. Additionally, two option periods shall also be quoted by the contractor. Option Year One's period shall be 04/1/2022 through 03/31/2023. Option Year Two's period shall be 04/1/2023 through 03/31/2024.

CLOSING STATEMENT

This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice.

An interested Offeror must be able to demonstrate its capabability to independently, and not as an agent of the Government, software that provides a comprehensive database of refined drug development information and serves as an efficient system to identify promising drugs, formulations, and models in the development phase. Drug information must be integrated in a single, flexible resource, and updated daily. The software must also include information about similar chemical structures of alternative compounds, the most relevant animal models used within the scientific industry for a specific target, and identify Pharmaceutical companies interested in investing in NIDA funded SBIR/STTR companies.

Responses to this notice must include sufficient information to establish the interested parties' bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Such factors may include: past performance; special features required for effective program performance; trade-in considerations; probable life of the item selected as compared with that of a comparable item; warranty considerations; maintenance availability; and environmental and energy efficiency considerations.

In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.

All responses must be received by March 19, 2021, 12:00 p.m. Eastern Time and must reference number 75N95021Q00113. Responses must be submitted electronically to Josh Lazarus, Contracting Officer at josh.lazarus@nih.gov and must reference the solicitation number 75N95021Q00113 on your electronic request. FAX requests are not accepted.

All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.